Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROR1-Specific Autologous T Cells in CLL/SLL
NCT02194374Phase 1Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2015
- Primary completion
- Jun 2017
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of ROR1R-CAR-T in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose at 4 weeks. Planned start Jan 2015; status: withdrawn.
02
Drugs
ROR1R-CAR-T
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT02194374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02194374.